Intellia Therapeutics (NTLA) Scheduled to Post Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is scheduled to be releasing its earnings data before the market opens on Thursday, November 7th. Analysts expect Intellia Therapeutics to post earnings of ($1.37) per share for the quarter.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to the consensus estimate of $19.68 million. The business’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same quarter last year, the company posted ($1.40) earnings per share. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Stock Up 0.1 %

Shares of Intellia Therapeutics stock traded up $0.02 during trading hours on Tuesday, reaching $15.16. 1,139,681 shares of the stock traded hands, compared to its average volume of 1,636,843. Intellia Therapeutics has a one year low of $13.95 and a one year high of $34.87. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -2.78 and a beta of 1.81. The company has a 50 day moving average price of $19.70 and a 200 day moving average price of $22.38.

Analysts Set New Price Targets

A number of brokerages have commented on NTLA. JPMorgan Chase & Co. reduced their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. The Goldman Sachs Group cut their price objective on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $54.00 target price on shares of Intellia Therapeutics in a report on Thursday, September 19th. Evercore ISI raised Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Finally, Robert W. Baird decreased their price objective on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $59.13.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.20% of the stock is currently owned by insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.